Polyanion–tobramycin nanocomplexes into functional microparticles for the treatment of Pseudomonas aeruginosa infections in cystic fibrosis

6533b7d8fe1ef96bd126b7b6

RESEARCH PRODUCT

Polyanion–tobramycin nanocomplexes into functional microparticles for the treatment of Pseudomonas aeruginosa infections in cystic fibrosis

Dario Spigolon Dario Spigolon Domenico Schillaci Gennara Cavallaro Maria Grazia Cusimano Emanuela Fabiola Craparo Gaetano Giammona Barbara Porsio

subject

Pseudomonas aeruginosa infection Cystic Fibrosis Polymers medicine.drug_class Antibiotics Biomedical Engineering Medicine (miscellaneous)Bioengineering 02 engineering and technology Development Biology Settore BIO/19 - Microbiologia Generale nano into micro strategy Cystic fibrosis Cell Line Nanocomposites Microbiology 03 medical and health sciences 0302 clinical medicine Antibiotic resistance Pseudomonas aeruginosa Infections medicine Tobramycin Humans Mannitol Pseudomonas Infections General Materials Science Drug Carriers Epithelial Cells Penetration (firestop)021001 nanoscience & nanotechnology medicine.disease Polyelectrolytes Mucus Anti-Bacterial Agents Drug Liberation Mucus microparticle 030228 respiratory system Settore CHIM/09 - Farmaceutico Tecnologico Applicativo cystic fibrosis artificial mucu Pseudomonas aeruginosa Tobramycin Mannitol 0210 nano-technology α β-poly(N-2-hydroxyethyl)-D L-aspartamide spray dryer medicine.drug

description

Aim: Efficacy of antibiotics in cystic fibrosis (CF) is compromised by the poor penetration through mucus barrier. This work proposes a new ‘nano-into-micro’ approach, used to obtain a combinatorial effect: achieve a sustained delivery of tobramycin and overcome mucus barrier. Methods: Mannitol microparticles (MPs) were loaded with a tobramycin polymeric nanocomplex and characterized in presence of CF artificial mucus. Results & discussion: MPs are able to alter the rheological properties of CF artificial mucus, enhancing drug penetration into it and allowing a prolonged drug release. MPs resulted to be effective in Pseudomonas aeruginosa infections if compared with free tobramycin. Conclusion: MPs resulted to be a formulation of higher efficacy, with potential positive implications, as lower required dose, administration frequency, side effects and antibiotic resistance problems.

year	journal	country	edition	language
2016-11-24	Nanomedicine

https://doi.org/10.2217/nnm-2016-0262